Raltitrexed

TargetMol
Product Code: TAR-T6632
Supplier: TargetMol
CodeSizePrice
TAR-T6632-5mg5mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6632-1mL1 mL * 10 mM (in DMSO)£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6632-10mg10mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6632-25mg25mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6632-50mg50mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6632-100mg100mg£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6632-200mg200mg£468.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6632-500mg500mg£699.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Raltitrexed?IC50 of 9 nM?, a thymidylate synthase inhibitor, is used for the inhibition of L1210 cell growth.
CAS:
112887-68-0
Formula:
C21H22N4O6S
Molecular Weight:
458.49
Pathway:
DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.9906
SMILES:
CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)NC(CCC(O)=O)C(O)=O
Target:
Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis

References

Aschele C, et al. Clin Cancer Res, 1998, 4(5), 1323-1330. Van Cutsem E, et al. Ann Oncol, 2002, 13(4), 513-522. Wang D, et al. Cancer Chemother Pharmacol, 2006, 57(1), 97-104. Dong Y, et al. Raltitrexed's effect on the development of neural tube defects in mice is associated with DNA damage, apoptosis, and proliferation. Mol Cell Biochem. 2015 Jan;398(1-2):223-31. Di Gennaro E, et al. Cancer Biol Ther, 2009, 8(9), 782-791. Zhao H, et al. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res. 2016;23(5):237-48 Peters GJ, et al. Eur J Cancer, 2000, 36(7), 916-924.